aTyr Pharma Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
58
- Stock Symbol
-
ATYR
- Share Price
-
$6.11
- (As of Friday Closing)
aTyr Pharma General Information
Description
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Contact Information
Website
www.atyrpharma.comCorporate Office
- 3545 John Hopkins Court
- Suite 250
- San Diego, CA 92121
- United States
Corporate Office
- 3545 John Hopkins Court
- Suite 250
- San Diego, CA 92121
- United States
aTyr Pharma Stock Performance
As of 13-Nov-2026, aTyr Pharma’s stock price is $6.11. Its current market cap is $15.6M with 2.55M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.11 | $6.21 | $4.07 - $44.40 | $15.6M | 2.55M | 108K | -$21.64 |
aTyr Pharma Financials Summary
As of 30-Sep-2026, aTyr Pharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (16,593) | (1,301) | 251,268 | (4,530) |
| Revenue | 0 | 190 | 235 | 353 |
| EBITDA | (51,728) | (72,570) | (62,482) | (47,656) |
| Net Income | (53,324) | (74,118) | (64,023) | (50,389) |
| Total Assets | 59,806 | 93,003 | 96,830 | 120,653 |
| Total Debt | 10,919 | 12,033 | 13,283 | 15,095 |
aTyr Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
aTyr Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
aTyr Pharma Comparisons
Industry
Financing
Details
aTyr Pharma Competitors (71)
One of aTyr Pharma’s 71 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Rallybio | Formerly VC-backed | New Haven, CT | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
aTyr Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
aTyr Pharma Patents
aTyr Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025376905-A1 | Modified aspartyl-trna synthetases | Pending | 13-May-2024 | ||
| WO-2025240357-A1 | Modified aspartyl-trna synthetases | Pending | 13-May-2024 | ||
| US-20250216395-A1 | Compositions and methods comprising anti-nrp2 antibodies | Pending | 17-Jun-2022 | ||
| WO-2023245117-A2 | Compositions and methods comprising anti-nrp2 antibodies | Inactive | 17-Jun-2022 | ||
| WO-2023245117-A3 | Compositions and methods comprising anti-nrp2 antibodies | Inactive | 17-Jun-2022 | G01N33/5759 |
aTyr Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
aTyr Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
aTyr Pharma FAQs
-
When was aTyr Pharma founded?
aTyr Pharma was founded in 2005.
-
Where is aTyr Pharma headquartered?
aTyr Pharma is headquartered in San Diego, CA.
-
What is the size of aTyr Pharma?
aTyr Pharma has 58 total employees.
-
What industry is aTyr Pharma in?
aTyr Pharma’s primary industry is Drug Discovery.
-
Is aTyr Pharma a private or public company?
aTyr Pharma is a Public company.
-
What is aTyr Pharma’s stock symbol?
The ticker symbol for aTyr Pharma is ATYR.
-
What is the current stock price of aTyr Pharma?
As of 13-Nov-2026 the stock price of aTyr Pharma is $6.11.
-
What is the current market cap of aTyr Pharma?
The current market capitalization of aTyr Pharma is $15.6M.
-
Who are aTyr Pharma’s competitors?
Crinetics Pharmaceuticals, Rallybio, Ayala Pharmaceuticals, Adaptimmune Therapeutics, and CytomX Therapeutics are some of the 71 competitors of aTyr Pharma.
-
What is aTyr Pharma’s annual earnings per share (EPS)?
aTyr Pharma’s EPS for 12 months was -$21.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
